JP5868593B2 - Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 - Google Patents

Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 Download PDF

Info

Publication number
JP5868593B2
JP5868593B2 JP2010517161A JP2010517161A JP5868593B2 JP 5868593 B2 JP5868593 B2 JP 5868593B2 JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010517161 A JP2010517161 A JP 2010517161A JP 5868593 B2 JP5868593 B2 JP 5868593B2
Authority
JP
Japan
Prior art keywords
antibody
seq
variable region
chain variable
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010517161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533498A (ja
JP2010533498A5 (OSRAM
Inventor
ジョナサン・アレクサンダー・ターレット
リ−シェン・ル
ハイチュン・フアン
ダペン・ヤオ
チン・パン
ヘイディ・ルブラン
ティモシー・スプロール
マーク・ヤマナカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of JP2010533498A publication Critical patent/JP2010533498A/ja
Publication of JP2010533498A5 publication Critical patent/JP2010533498A5/ja
Application granted granted Critical
Publication of JP5868593B2 publication Critical patent/JP5868593B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
JP2010517161A 2007-07-17 2008-07-17 Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体 Expired - Fee Related JP5868593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95984507P 2007-07-17 2007-07-17
US60/959,845 2007-07-17
PCT/US2008/070344 WO2009012394A1 (en) 2007-07-17 2008-07-17 Monoclonal antibodies against glypican-3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014137921A Division JP2014236734A (ja) 2007-07-17 2014-07-03 Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2010533498A JP2010533498A (ja) 2010-10-28
JP2010533498A5 JP2010533498A5 (OSRAM) 2011-07-21
JP5868593B2 true JP5868593B2 (ja) 2016-02-24

Family

ID=39874207

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010517161A Expired - Fee Related JP5868593B2 (ja) 2007-07-17 2008-07-17 Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体
JP2014137921A Pending JP2014236734A (ja) 2007-07-17 2014-07-03 Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014137921A Pending JP2014236734A (ja) 2007-07-17 2014-07-03 Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体

Country Status (18)

Country Link
US (2) US8680247B2 (OSRAM)
EP (1) EP2178921B1 (OSRAM)
JP (2) JP5868593B2 (OSRAM)
KR (2) KR101570252B1 (OSRAM)
CN (1) CN101815726B (OSRAM)
AU (1) AU2008275985B2 (OSRAM)
CY (1) CY1117236T1 (OSRAM)
DK (1) DK2178921T3 (OSRAM)
ES (1) ES2562790T3 (OSRAM)
HR (1) HRP20160270T1 (OSRAM)
HU (1) HUE028737T2 (OSRAM)
ME (1) ME02345B (OSRAM)
MX (1) MX2010000537A (OSRAM)
PL (1) PL2178921T3 (OSRAM)
PT (1) PT2178921E (OSRAM)
RS (1) RS54624B1 (OSRAM)
SI (1) SI2178921T1 (OSRAM)
WO (1) WO2009012394A1 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
IN2014DN10515A (OSRAM) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
HUE028737T2 (en) 2007-07-17 2017-01-30 Squibb & Sons Llc Monoclonal antibodies against glypican-3
AU2008304778B9 (en) 2007-09-26 2014-05-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CN101809162B (zh) * 2007-09-28 2013-06-05 中外制药株式会社 血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
TW201422237A (zh) 2009-05-08 2014-06-16 Genentech Inc 人類化之抗-ｅｇｆｌ７抗體及其使用方法
WO2012065978A1 (en) 2010-11-15 2012-05-24 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
KR102447595B1 (ko) 2010-11-30 2022-09-26 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
CA2822947A1 (en) * 2010-12-28 2012-07-05 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
EP2699603B1 (en) * 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
CN105073139B (zh) 2013-02-14 2019-01-11 百时美施贵宝公司 妥布赖森化合物、制备和使用方法
CA2921401A1 (en) 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
MX386942B (es) 2014-11-21 2025-03-19 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
PE20171185A1 (es) 2015-01-14 2017-08-22 Bristol Myers Squibb Co Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
BR112017014599A2 (pt) 2015-01-14 2018-01-16 Bristol-Myers Squibb Company dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
CN107922951B (zh) * 2015-06-24 2022-01-14 学校法人庆应义塾 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体
CN106397593B (zh) * 2015-08-03 2019-09-10 科济生物医药（上海）有限公司 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
CA3008678A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
CN105717303A (zh) * 2016-01-29 2016-06-29 山东康力医疗器械科技有限公司 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN106084041A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种全人源抗GPC3的全分子IgG抗体及其应用
CA3031846A1 (en) 2016-07-26 2018-02-01 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
JP7023933B2 (ja) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
JP7295030B2 (ja) 2017-04-26 2023-06-20 ユーリカ セラピューティックス， インコーポレイテッド グリピカン３を特異的に認識するコンストラクト及びその使用
CA3064321A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
IL278938B2 (en) 2018-05-29 2024-09-01 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US20220119533A1 (en) 2018-10-23 2022-04-21 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
KR20210096167A (ko) 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
EP3886914B1 (en) 2018-11-30 2023-03-29 Bristol-Myers Squibb Company Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
SG11202110390XA (en) * 2019-03-21 2021-10-28 Agency Science Tech & Res Composition
JP7644777B2 (ja) 2020-04-22 2025-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
KR20230007452A (ko) * 2020-05-07 2023-01-12 페인스 테라퓨틱스 인코포레이티드 항종양 관련 항원 항체 및 이의 용도
CA3205422A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
JP2024515201A (ja) * 2021-04-23 2024-04-05 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｇｐｃ３抗体及び使用方法
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
JP2024534806A (ja) * 2021-08-19 2024-09-26 アディセット セラピューティクス， インク． 膜結合型グリピカン３の検出方法
US20240409663A1 (en) * 2021-10-15 2024-12-12 Concept To Medicine Biotech Co., Ltd. Anti-glypican 3 antibodies
JP2025535713A (ja) 2022-10-07 2025-10-28 アンブレツクス・インコーポレイテツド 薬物リンカー及びその抗体コンジュゲート
CN120051491A (zh) * 2022-11-01 2025-05-27 上海齐鲁制药研究中心有限公司 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426001B2 (ja) 1993-09-16 2003-07-14 東芝機械株式会社 ステージ内蔵型雰囲気室装置
AU5632296A (en) * 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE483801T1 (de) 2001-06-22 2010-10-15 Chugai Pharmaceutical Co Ltd Zellproliferationshemmer, die anti-glypican 3 antikörper enthalten
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004067571A1 (fr) 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
US7745822B2 (en) 2003-06-27 2010-06-29 Nec Corporation Thin film transistor and thin film transistor substrate including a polycrystalline semiconductor thin film having a large heat capacity part and a small heat capacity part
CN111925445A (zh) * 2004-07-09 2020-11-13 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
PL1800693T3 (pl) 2004-08-24 2013-12-31 Chugai Pharmaceutical Co Ltd Terapia adiuwantowa z zastosowaniem przeciwciała przeciw glipikanowi 3
EP1816140A4 (en) * 2004-10-26 2009-09-02 Chugai Pharmaceutical Co Ltd ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN
WO2006137931A2 (en) * 2005-03-14 2006-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serivces Human monoclonal antibodies against hendra and nipah viruses
AU2006265108C1 (en) * 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US7744800B2 (en) * 2006-01-06 2010-06-29 Molded Fiber Glass Companies Method and apparatus for controlling the stacking height of stackable products during compression molding off stops
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
HUE028737T2 (en) * 2007-07-17 2017-01-30 Squibb & Sons Llc Monoclonal antibodies against glypican-3
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use

Also Published As

Publication number Publication date
WO2009012394A1 (en) 2009-01-22
KR20100056467A (ko) 2010-05-27
KR101570252B1 (ko) 2015-11-19
PL2178921T3 (pl) 2016-06-30
ES2562790T3 (es) 2016-03-08
JP2010533498A (ja) 2010-10-28
EP2178921A1 (en) 2010-04-28
MX2010000537A (es) 2010-03-25
SI2178921T1 (sl) 2016-05-31
HUE028737T2 (en) 2017-01-30
US20140186892A1 (en) 2014-07-03
CN101815726A (zh) 2010-08-25
HRP20160270T1 (hr) 2016-05-06
JP2014236734A (ja) 2014-12-18
CN101815726B (zh) 2013-04-03
KR20150038732A (ko) 2015-04-08
CY1117236T1 (el) 2017-04-05
AU2008275985A1 (en) 2009-01-22
US20100209432A1 (en) 2010-08-19
KR101527342B1 (ko) 2015-06-09
DK2178921T3 (en) 2016-04-04
AU2008275985B2 (en) 2013-09-19
EP2178921B1 (en) 2016-01-06
US9217033B2 (en) 2015-12-22
PT2178921E (pt) 2016-03-23
US8680247B2 (en) 2014-03-25
RS54624B1 (sr) 2016-08-31
ME02345B (me) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5868593B2 (ja) Ｇｌｙｐｉｃａｎ−３に対するモノクローナル抗体
US11312777B2 (en) Human monoclonal antibodies that bind CXCR4 and uses thereof
KR101373464B1 (ko) 단백질 티로신 키나제 7(ｐｔｋ7)에 대한 인간 단일클론항체 및 그의 용도
JP5897051B2 (ja) フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
JP2009509510A (ja) Ｃｄ７０に対するヒトモノクローナル抗体
JP2008526260A (ja) Ｉｒｔａ−２抗体およびその使用法
AU2013257387A1 (en) Monoclonal antibodies against glypican-3
MX2008006792A (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130507

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130806

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140801

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160106

R150 Certificate of patent or registration of utility model

Ref document number: 5868593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees